WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) — Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a complicated clinical-stage biotechnology firm targeted on elevating the following period of weight problems care, right this moment introduced the pricing of its preliminary public providing of 39,062,500 shares of its widespread inventory at a worth to the general public of $16.00 per share. The entire shares of widespread inventory are being supplied by Kailera. The gross proceeds from the providing, earlier than deducting underwriting reductions and commissions and providing bills payable by Kailera, are anticipated to be $625.0 million, excluding any train of the underwriters’ choice to buy extra shares. Kailera’s widespread inventory is anticipated to start buying and selling on the Nasdaq International Choose Market below the ticker image “KLRA” on April 17, 2026. The providing is anticipated to shut on April 20, 2026, topic to the satisfaction of customary closing situations. As well as, Kailera has granted the underwriters a 30-day choice to buy as much as an extra 5,859,375 shares of widespread inventory on the preliminary public providing worth much less underwriting reductions and commissions.
J.P. Morgan, Jefferies, Leerink Companions, TD Cowen and Evercore ISI are performing as joint book-running managers for the providing. William Blair is performing as lead supervisor for the providing.
This press launch doesn’t represent a suggestion to promote or a solicitation of a suggestion to purchase these securities, nor shall there be any provide or sale of those securities in any state or jurisdiction by which such provide, solicitation or sale can be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.
